McNeil Sales Still Slowed By Pseudoephedrine Limits
This article was originally published in The Tan Sheet
Executive Summary
Pseudoephedrine restrictions were the primary driver behind a 7% decline in first-quarter U.S. sales for Johnson & Johnson's McNeil Consumer division, J&J reported during an April 18 earnings call